STAT+: Lilly wins approval for once-weekly insulin shot
The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersThe Justice Department said in June that it would no longer enforce laws that prioritized people with disabilities living and receiving services in their communities, rather than in nursing homes…
By Chella·3h ago
Why it mattersPresident Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion access
By Chella·2h ago
Why it matters“A discrepancy between how federal and state public health officials determine measles deaths will only increase public confusion,” write Denys T. Lau and Jennifer D.
“A discrepancy between how federal and state public health officials determine measles deaths will only increase public confusion,” write Denys T. Lau and Jenni…
By Chella·7h ago
Why it mattersAdvanced Research Projects Agency for Health is planning a total-lifespan research project on autism: A Q&A with its leader, Russell Shilling.
By Chella·7h ago